Miltenyi Biotec B.V. & Co. KG
Miltenyi Biotec B.V. & Co. KG is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in Living Donor Renal Transplant Recipients
Sponsor Sangamo Therapeutics France
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Recruitment was permanently stopped before full enrolment was achieved, resulting in a smaller-than-planned sample size.
- Early recruitment termination meant that the planned Bayesian Optimal Interval dose-escalation process did not meet its pre-specified stopping criteria.
- Limited available biopsy material constrained interpretation of chronic graft-related findings.
- Mixed lymphocyte reaction assay data were limited by low peripheral blood mononuclear cell availability after anti-thymocyte globulin lymphodepletion, precluding conclusions.
These findings describe the trial, not the service provider’s performance or responsibility.
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
- Not reported
A single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric subjects with relapsed/refractory (r/r) mature B-cell neoplasms who have relapsed after one or more prior therapies, including subjects with primary refractory disease
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Sponsor USWM Ct LLC
- Start (EU)
- Latest update
- Estimated end
A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Miltenyi Biotec B.V. & Co. KG?
The 2026-10-09 snapshot links Miltenyi Biotec B.V. & Co. KG to 7 distinct CTIS trials. Recorded services include Laboratory services, Medicinal product management, IMP Manufacterer, Investigational Medicinal Product Manufacturer, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Miltenyi Biotec B.V. & Co. KG?
The most frequently recorded therapeutic areas are Haematological Malignancies, Nephrology, Solid Tumor Oncology, Transplantation. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Miltenyi Biotec B.V. & Co. KG conducted?
The linked trials record locations in 15 countries, including Germany, Netherlands, France, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Miltenyi Biotec B.V. & Co. KG delivered services.
What can this page tell me about Miltenyi Biotec B.V. & Co. KG's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Miltenyi Biotec B.V. & Co. KG. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Miltenyi Biotec B.V. & Co. KG